Radioantibody startup led by prostate cancer experts raises $90M

Lei Lei Wu

News Reporter

Neil Bander’s lab developed the first antibodies that target PSMA — a marker on prostate cancer cells that would much later become the target for Novartis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Radioantibody startup led by prostate cancer experts raises $90M

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ra­dioan­ti­body start­up led by prostate can­cer ex­perts rais­es $90M

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Radioantibody startup led by prostate cancer experts raises $90M